BILTHOVEN, The Netherlands, July 22 — InteRNA Genomics B.V. and Applied Biosystems Inc. announce signing of a Software Community Commercial Membership Agreement regarding the exchange of InteRNA’s information and software tools related to Applied Biosystems’ SOLiD(TM) technology, InteRNA and Applied Biosystems will co-market InteRNA’s small RNA bioinformatics pipeline, miR-Intess(TM), for users of Applied Biosystems’ SOLiD(TM) System that enables massively parallel sequencing.

The Applied Biosystems SOLiD(TM) System is a revolutionary genetic analysis platform that enables ultra-high-throughput (U-HTP) or massively parallel sequencing (MPS) of clonally amplified DNA fragments linked to beads. The sequencing methodology is based on sequential ligation with dye-labeled oligonucleotides. The ultra-high-throughput capability and the unmatched accuracy inherent in the SOLiD(TM) System, coupled with broad application flexibility, provide a unique system for advancing genome research and personalized genomics, where each individual can have its own genome sequenced.

While the generation of MPS data can be outsourced to a number of sequencing service providers, data processing and interpretation requires highly skilled bioinformaticians and a dedicated computational infrastructure – a challenge for many organizations. InteRNA Genomics delivers complete, up-to-date and ready-to-interpret analyses of raw sequencing data, allowing the researcher to focus on the biological problem at hand. The informatics solutions are modular and easily customized, enabling development of data analysis pipelines that take into account specifics of every individual project.

The basic miR-Intess(TM) pipeline generates extensive tabular as well as graphical output. Besides sample and sequencing statistics, comprehensive data on known and candidate novel microRNAs (miRNAs) are provided, allowing simultaneous digital expression profiling and small RNA discovery. Furthermore, links to state-of-the-art miRNA target predictions and public databases are provided. Customized solutions and pipeline extensions are available on request.

“The participation of InteRNA Genomics in our SOLiD(TM) System software community program is another concrete example of Applied Biosystems’ dedication to deliver new, cutting edge products and services to the next generation sequencing community. Our goal is to provide our customers with the best information and software tools available for the analysis of raw data sets,” said Roger Canales, Genetic Analysis Software Community Program Manager at Applied Biosystems.

“We are very much honored to join Applied Biosystems’ SOLiD(TM) System software community program. This agreement further validates and confirms the key benefits of our bioinformatics pipeline for the analysis of MPS data sets,” said Roel Schaapveld, Chief Operating Officer of InteRNA Genomics. “Our expertise in small RNA analysis perfectly addresses the exponential gain in attention for research into small regulatory RNA molecules and miRNAs in particular.”

About InteRNA Genomics B.V.

InteRNA Genomics B.V., a subsidiary of InteRNA Technologies B.V. and based in Bilthoven, the Netherlands, offers services and software for processing, analyzing and presenting ultra-high-throughput sequencing data generated by various platforms. InteRNA’s proprietary informatics solutions, Intess(TM), convert large sets of raw sequencing data into interpretable formats and integrate this information with existing proprietary and public data resources.

InteRNA Genomics is co-founded by Aglaia Biomedical Ventures and Dr. Eugene Berezikov and Dr. Edwin Cuppen, leading scientists in U-HTP data generation and analysis. Berezikov and Cuppen pioneered the application of high-throughput sequencing technologies for expression profiling and discovery of small RNAs and miRNAs in particular, as described in several high-profile papers.

More information on InteRNA can be accessed at https://www.interna-genomics.com.

SOURCE InteRNA Genomics